

The human β -globin as a model to study quality control of gene expression in the nucleus


Noélia Custódio




Instituto de Medicina Molecular
Faculdade de Medicina
Universidade de Lisboa



13 April 2010



Thalassemia like human β -globin transcripts are not exported to the cytoplasm





Retention in the nucleus of incorrectly processed transcripts

Working Hypothesis: A quality control mechanism must exist in the nucleus to retain the incorrectly processed transcripts


Goals of the work: Elucidate this quality control mechanism

- 1) Determine the intranuclear localisation of the retained transcripts
- 2) Identify the molecular players responsible for the retention


Model system: MEL cells stable transfected with the human β -globin gene




Human β -globin RNA is detected at the transcription site



Inefficient processing impairs release of RNA from the site of transcription



β -globin RNA processing mutants remain at the transcription site in cells treated with act.D




The quality control mechanism responsible for the nuclear retention of incorrectly processed transcripts operates at the site of transcription

What are the molecular players involved in the quality control mechanism that operates at the transcription site?

Working Hypothesis:


1. Proteins essential for the release and/or transport of the transcripts from the gene locus are not recruited to mutant transcripts
2. The retention is mediated by proteins that are bound to the nascent transcripts and become stalled due to incomplete processing

Transcription cycle and pre-mRNA processing




The processing mutants analyzed are able to assemble at least partially the processing machinery

Transcription cycle and pre-mRNA processing




The release of the mutant transcripts from the transcription site could be blocked by the stalled or abnormal processing machinery associated with the CTD


Establishment of MEL cell clones expressing α -amanitin resistant RNA Pol II LS with mutated versions of the CTD



Transcription of human β -globin gene by exogenous α -amanitin resistant RNA Pol II LS



$\Delta 31$ CTD truncation impairs release of β WT RNA from the transcription site but has no effect on the retention of the splicing-defective RNA



Custódio N. *et al.*, JCB (2007)

Why are transcripts synthesized by RNA Pol II $\Delta 31$ retained at the site of transcription?

Truncation of the CTD reduces the efficiency of capping, splicing and 3' end cleavage.

McCracken *et al.*, Nature (1997)


McCracken *et al.*, G&D (1997)

Fong & Bentley G&D (2001)

Are the RNA Pol II $\Delta 31$ transcripts correctly processed?

RNA transcribed by RNA Pol II LS $\Delta 31$ is spliced



RNase protection assay




Custódio N. *et al.*, JCB (2007)

RNA transcribed by RNA Pol II LS $\Delta 31$ is 3' end cleaved and polyadenylated

RNase protection assay



Poly(A) tail length analysis (LM-PAT assay)



The CTD repeats missing in the $\Delta 31$ mutant are required for transcription site release but not for pre-mRNA processing


Custódio N. *et al.*, JCB (2007)

The CTD is necessary for recruitment of splicing factors to sites of transcription in vivo.


Misteli and Spector, *Mol Cell* (1999)

Are the missing repeats in CTD $\Delta 31$ preventing the recruitment of proteins required for release of the transcripts?

In vivo recruitment of exon-junction complex proteins to transcription sites in the nucleus



EJC proteins are recruited to nascent transcripts synthesized by RNA Pol. II LS Δ31



Custódio N. *et al.*, JCB (2007)

In yeast, transcription site retention of abnormally processed transcripts requires the nuclear exosome subunit Rrp6.

Hilleren *et al.*, Nature (2001)

Libri *et al.*, MCB (2002)


The exosome is a complex of 3' to 5' exoribonucleases

Initially identified as an activity required for the 3'-end processing of rRNA precursors

Components named Rrp (rRNA-processing) proteins


Participates in most nuclear and cytoplasmic 3' to 5' RNA -degradation and -processing pathways

	Domains	Archaea ^b	<i>S. cerevisiae</i> ^c	Loc ^d	Human ^e	Loc ^d
Exosome core	RNasePH	Rrp41	Rrp41 p (Ski6p)	n+c	hRrp41 (hSki6; EXOS4)	n+c
		Rrp42	Rrp42p	n+c	hRrp42 (EXOS7)	n+c
		(Rrp41)	Rrp46p	n+c	hRrp46 (EXOS5)	n+c
		(Rrp42)	Rrp43p	n+c	hRrp43 (OIP2; EXOS8)	n+c
		(Rrp41)	Mtr3p	n+c	hMtr3 (EXOS6)	n+c
		(Rrp42)	Rrp45p	n+c	hRrp45 (Pm/Sci-75; EXOS9)	n+c
		Rrp4	Rrp4p	n+c	hRrp4 (EXOS2)	n+c
		(Rrp4)	Rrp40p	n+c	hRrp40 (EXOS3)	n+c
		Csl4	Csl4p	n+c	hCsl4 (EXOS1)	n+c
Exonuclease	RNase II	—	Rrp44p (Dis3p)	n+c	hRrp44 (hDis3)	n+c
	RNase D	—	Rrp6p	n	hRrp6 (PM/Sci-100; EXOS10)	n+c



Schmid & Torben, TBS (2008)

PM/ScI-100 (hRrp6) exosome subunit is recruited to nascent transcripts synthesized by RNA Pol. II LS $\Delta 31$




Recruitment of neither EJC proteins nor nuclear exosome Rrp6 class of proteins to nascent mRNA is sufficient for its release from the site of transcription


Working hypothesis

The $\Delta 31$ CTD truncation mutant may be impaired to recruit protein factors required to complete the maturation of spliced and 3' end processed mRNA into export-competent mRNPs.


wt CTD



$\Delta 31$ CTD




Conclusions



mRNA release from the site of transcription is an important step in mRNA biogenesis and an important checkpoint for mRNA integrity

The CTD is involved in processes that control the release of the mRNA from the site of transcription by a mechanism independent of pre-mRNA processing

Quality Control of mRNA biogenesis



Checkpoints are operating in the nucleus to ensure the quality of the mRNA that cross the NPC and reach the translation machinery in the cytoplasm

What are the molecular mechanisms for this checkpoints?

Acknowledgements

Maria Carmo-Fonseca

Instituto de Medicina Molecular, Lisboa

Michael Antoniou

King's College London School of Medicine, London

Fundação para a Ciência e Tecnologia, Portugal